DÄ internationalArchive20/2019Antidepressant withdrawal and rebound phenomena

Review article

Antidepressant withdrawal and rebound phenomena

A systematic review

Dtsch Arztebl Int 2019; 116(20): 355-61; DOI: 10.3238/arztebl.2019.0355

Henssler, J; Heinz, A; Brandt, L; Bschor, T

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Psychiatrische Universitätsklinik der Charité im St. Hedwig-Krankenhaus,
Campus Charité Mitte, Charité Universitätsmedizin Berlin: Dr. med. Jonathan Henssler,
Lasse Brandt
Abteilung für Psychiatrie, Schlosspark-Klinik, Berlin: Prof. Dr. med. Tom Bschor
Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum Carl Gustav Carus,
Technische Universität Dresden: Prof. Dr. med. Tom Bschor
Klinik für Psychiatrie und Psychotherapie, Campus Charité Mitte,
Charité Universitätsmedizin Berlin: Prof. Dr. med. Dr. phil. Andreas Heinz
1.Schwabe U, Ludwig WD: Arzneiverordnungen 2017 im Überblick. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J, eds.: Arzneiverordnungs-Report 2018. Berlin, Heidelberg: Springer 2018; 3–26 CrossRef
2.Dilsaver SC, Greden JF: Antidepressant withdrawal phenomena. Biol Psychiatry 1984; 19: 237–56.
3.DGPPN, BÄK, KBV, AWMF: für die Leitliniengruppe Unipolare Depression. S3-Leitlinie/Nationale VersorgungsLeitlinie Unipolare Depression-Langfassung. AWMF-Register Nr nvl-005 www.awmforg/leitlinien/detail/ll/nvl-005html (last accessed on 27 December 2017).
4.Baldwin DS, Cooper JA, Huusom AK, Hindmarch I: A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. Int Clin Psychopharmacol 2006; 21: 159–69 CrossRef MEDLINE
5.Fava GA, Gatti A, Belaise C, Guidi J, Offidani E: Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom 2015; 84: 72–81 CrossRef MEDLINE
6.Chouinard G, Chouinard VA: New classification of selective serotonin reuptake inhibitor withdrawal. Psychother Psychosom 2015; 84: 63–71 CrossRef MEDLINE
7.Michelson D, Amsterdam J, Apter J, et al.: Hormonal markers of stress response following interruption of selective serotonin reuptake inhibitor treatment. Psychoneuroendocrinology 2000; 25: 169–77 CrossRef
8.Zajecka J, Fawcett J, Amsterdam J, et al.: Safety of abrupt discontinuation of fluoxetine: a randomized, placebo-controlled study. J Clin Psychopharmacol 1998; 18: 193–7 CrossRef MEDLINE
9.Allgulander C, Florea I, Huusom AK: Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 2006; 9: 495–505 CrossRef MEDLINE
10.Markowitz JS, DeVane CL, Liston HL, Montgomery SA: An assessment of selective serotonin reuptake inhibitor discontinuation symptoms with citalopram. Int Clin Psychopharmacol 2000; 15: 329–33 CrossRef
11.Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger JP: A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005; 66: 1270–8 CrossRef
12.Kaufman MJ, Henry ME, Frederick B, et al.: Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. Biol Psychiatry 2003; 54: 534–9 CrossRef
13.Montgomery SA, Huusom AK, Bothmer J: A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology 2004; 50: 57–64 CrossRefMEDLINE
14.GlaxoSmithKline: A double-blind comparative study of withdrawal effects following abrupt discontinuation of treatment with paroxetine in low or high dose or imipramine. GSK – Clinical Study Register 1992; www.gsk-clinicalstudyregister.com (last accessed on 27 December 2017).
15.Ninan PT, Musgnung J, Messig M, Buckley G, Guico-Pabia CJ, Ramey TS: Incidence and timing of taper/posttherapy-emergent adverse events following discontinuation of desvenlafaxine 50 mg/d in patients with major depressive disorder. Prim Care Companion CNS Disord 2015; 17 CrossRef MEDLINE PubMed Central
16.Saxe PA, Arnold LM, Palmer RH, Gendreau RM, Chen W: Short-term (2-week) effects of discontinuing milnacipran in patients with fibromyalgia. Curr Med Res Opin 2012; 28: 815–21 CrossRef MEDLINE
17.Giller E, Bialos D, Harkness L, Jatlow P, Waldo M: Long-term amitriptyline in chronic depression. Hillside J Clin Psychiatry 1985; 7: 16–33.
18.Charney DS, Heninger GR, Sternberg DE, Landis H: Abrupt discontinuation of tricyclic antidepressant drugs: evidence for noradrenergic hyperactivity. Br J Psychiatry 1982; 141: 377–86 CrossRef
19.Gahr M, Schonfeldt-Lecuona C, Kolle MA, Freudenmann RW: Withdrawal and discontinuation phenomena associated with tranylcypromine: a systematic review. Pharmacopsychiatry 2013; 46: 123–9 CrossRef MEDLINE
20.Goodwin GM, Emsley R, Rembry S, Rouillon F: Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: a 24-week randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2009; 70: 1128–37 CrossRef MEDLINE
21.Stein DJ, Ahokas A, Albarran C, Olivier V, Allgulander C: Agomelatine prevents relapse in generalized anxiety disorder: a 6-month randomized, double-blind, placebo-controlled discontinuation study. J Clin Psychiatry 2012; 73: 1002–8 CrossRef MEDLINE
22.Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I: Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004; 19: 271–80 CrossRef
23.Davies J, Read J: A systematic review into the incidence, severity and duration of antidepressant withdrawal effects: Are guidelines evidence-based? Addict Behav 2018; pii: S0306–4603(18)30834–7 CrossRef
24.Khan A, Musgnung J, Ramey T, Messig M, Buckley G, Ninan PT: Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d. J Clin Psychopharmacol 2014; 34: 365–8 CrossRef MEDLINE
25.Tint A, Haddad PM, Anderson IM: The effect of rate of antidepressant tapering on the incidence of discontinuation symptoms: a randomised study. J Psychopharmacol 2008; 22: 330–2 CrossRef MEDLINE
26.Ellison JM: SSRI withdrawal buzz. J Clin Psychiatry 1994; 55: 544–5.
27.Fava GA, Bernardi M, Tomba E, Rafanelli C: Effects of gradual discontinuation of selective serotonin reuptake inhibitors in panic disorder with agoraphobia. Int J Neuropsychopharmacol 2007; 10: 835–8 CrossRef MEDLINE
28.Andrews PW, Kornstein SG, Halberstadt LJ, Gardner CO, Neale MC: Blue again: perturbational effects of antidepressants suggest monoaminergic homeostasis in major depression. Front Psychol 2011; 2: 159 CrossRef MEDLINE PubMed Central
29.Harvey BH, Slabbert FN: New insights on the antidepressant discontinuation syndrome. Hum Psychopharmacol 2014; 29: 503–16 CrossRef MEDLINE
30.Dilsaver SC, Feinberg M, Greden JF: Antidepressant withdrawal symptoms treated with anticholinergic agents. Am J Psychiatry 1983; 140: 249–51 CrossRefMEDLINE
31.Beesdo K, Bittner A, Pine DS, et al.: Incidence of social anxiety disorder and the consistent risk for secondary depression in the first three decades of life. Arch Gen Psychiatry 2007; 64: 903–12 CrossRef MEDLINE
32.Wittchen HU, Beesdo K, Bittner A, Goodwin RD: Depressive episodes–evidence for a causal role of primary anxiety disorders? Eur Psychiatry 2003; 18: 384–93 CrossRef MEDLINE
33.Boschloo L, Spijker AT, Hoencamp E, et al.: Predictors of the onset of manic symptoms and a (hypo) manic episode in patients with major depressive disorder. PLoS One 2014; 9: e106871 CrossRef MEDLINE PubMed Central
34.Fava M, Schmidt ME, Zhang S, Gonzales J, Raute NJ, Judge R: Treatment approaches to major depressive disorder relapse. Part 2: reinitiation of antidepressant treatment. Psychother Psychosom 2002; 71: 195–9 CrossRef MEDLINE
35.Fava GA, Rafanelli C, Grandi S, Canestrari R, Morphy MA: Six-year outcome for cognitive behavioral treatment of residual symptoms in major depression. Am J Psychiatry 1998; 155: 1443–5 CrossRef MEDLINE
36.Fava M, Detke MJ, Balestrieri M, Wang F, Raskin J, Perahia D: Management of depression relapse: re-initiation of duloxetine treatment or dose increase. J Psychiatr Res 2006; 40: 328–36 CrossRef MEDLINE
37.Fournier JC, DeRubeis RJ, Hollon SD, et al.: Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303: 47–53 CrossRef MEDLINE PubMed Central
38.Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT: Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 2008; 5: e45 CrossRef MEDLINE PubMed Central
39.Cipriani A, Furukawa TA, Salanti G, et al.: Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 2018; 391: 1357–66 CrossRef
40.Heinz A, Daedelow L, Wackerhagen C, Di Chiara G: Addiction theory matters—why there is no dependence on caffeine or antidepressant medication. Addict Biol 2019: (in press).
e1.Kramer JC, Klein DF, Fink M: Withdrawal symptoms following dicontinuation of imipramine therapy. Am J Psychiatry 1961; 118: 549–50 CrossRef MEDLINE
e2.Hotopf M, Hardy R, Lewis G: Discontinuation rates of SSRIs and tricyclic antidepressants: a meta-analysis and investigation of heterogeneity. Br J Psychiatry 1997; 170: 120–7 CrossRef
e3.Van Geffen EC, Brugman M, Van Hulten R, Bouvy ML, Egberts AC, Heerdink ER: Patients‘ concerns about and problems experienced with discontinuation of antidepressants. Int J Pharm Pract 2007; 15: 291–3 CrossRef
e4.Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB: Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry 1998; 44: 77–87 CrossRef
e5.Berber MJ: FINISH: remembering the discontinuation syndrome. Flu-like symptoms, Insomnia, Nausea, Imbalance, Sensory disturbances, and Hyperarousal (anxiety/agitation). J Clin Psychiatry 1998; 59: 255 CrossRef MEDLINE
e6. Hartford J, Kornstein S, Liebowitz M, et al.: Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. Int Clin Psychopharmacol 2007; 22: 167–74 CrossRef MEDLINE
e7.Montgomery SA, Andersen HF: Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol 2006; 21: 297–309 CrossRef
e8.Sir A, D‘Souza RF, Uguz S, et al.: Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms. J Clin Psychiatry 2005; 66: 1312–20 CrossRef MEDLINE
e9.Perahia DG, Kajdasz DK, Desaiah D, Haddad PM: Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005; 89: 207–12 CrossRef MEDLINE
e10.Vandel P, Sechter D, Weiller E, et al.: Post‐treatment emergent adverse events in depressed patients following treatment with milnacipran and paroxetine. Hum Psychopharmacol 2004; 19: 585–6 CrossRef MEDLINE
e11.McGrath PJ, Stewart JW, Tricamo E, Nunes EN, Quitkin FM: Paradoxical mood shifts to euthymia or hypomania upon withdrawal of antidepressant agents. J Clin Psychopharmacol 1993; 13: 224–5 CrossRef
e12.Tyrer P: Clinical effects of abrupt withdrawal from tri-cyclic antidepressants and monoamine oxidase inhibitors after long-term treatment. J Affect Disord 1984; 6: 1–7 CrossRef
e13.MacCall C, Callender J: Mirtazapine withdrawal causing hypomania. Br J Psychiatry 1999; 175: 390 CrossRef
e14.Fauchere PA: Recurrent, persisting panic attacks after sudden discontinuation of mirtazapine treatment: a case report. Int J Psychiatry Clin Pract 2004; 8: 127–9 CrossRef MEDLINE
e15.Berigan TR: Bupropion-associated withdrawal symptoms revisited: a case report. Prim Care Companion J Clin Psychiatry 2002; 4: 78 CrossRef
e16.Mirin SM, Schatzberg AF, Creasey DE: Hypomania and mania after withdrawal of tricyclic antidepressants. Am J Psychiatry 1981; 138: 87–9 CrossRef MEDLINE
e17.Rothschild AJ: Mania after withdrawal of isocarboxazid. J Clin Psychopharmacol 1985; 5: 340–2 CrossRef
e18.Bloch M, Stager SV, Braun AR, Rubinow DR: Severe psychiatric symptoms associated with paroxetine withdrawal. Lancet 1995; 346: 57 CrossRef
e19.Stoukides JA, Stoukides CA: Extrapyramidal symptoms upon discontinuation of fluoxetine. Am J Psychiatry 1991; 148: 1263 CrossRef
e20.Sathananthan GL, Gershon S: Imipramine withdrawal: an Akathisia like syndrome. Am J Psychiatry 1973; 130: 1286–7 CrossRef MEDLINE
e21.Goldstein TR, Frye MA, Denicoff KD, et al.: Antidepressant discontinuation-related mania: critical prospective observation and theoretical implications in bipolar disorder. J Clin Psychiatry 1999; 60: 563–7 CrossRef MEDLINE
e22.Wolfe RM: Antidepressant withdrawal reactions. Am Fam Physician 1997; 56: 455–62.
e23.Reeves RR, Mack JE, Beddingfield JJ: Shock-like sensations during venlafaxine withdrawal. Pharmacotherapy 2003; 23: 678–81 CrossRef
e24.Cosci F, Chouinard G, Chouinard V-A, Fava GA: The diagnostic clinical interview for drug withdrawal 1 (DID-W1)–new symptoms of selective serotonin reuptake inhibitors (SSRI) or serotonin Norepinephrine reuptake inhibitors (SNRI): inter-rater reliability. Riv Psichiatr 2018; 53: 95–9.
e25.Bhanji NH, Chouinard G, Kolivakis T, Margolese HC: Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. Can J Clin Pharmacol 2006; 13: e69–74.
e26.Belaise C, Gatti A, Chouinard VA, Chouinard G: Persistent postwithdrawal disorders induced by paroxetine, a selective serotonin reuptake inhibitor, and treated with specific cognitive behavioral therapy. Psychother Psychosom 2014; 83: 247–8 CrossRef MEDLINE
e27.Belaise C, Gatti A, Chouinard VA, Chouinard G: Patient online report of selective serotonin reuptake inhibitor-induced persistent postwithdrawal anxiety and mood disorders. Psychother Psychosom 2012; 81: 386–8 CrossRef MEDLINE
e28.El-Mallakh RS, Briscoe B: Studies of long-term use of antidepressants. CNS Drugs 2012; 26: 97–109 CrossRef MEDLINE
e29.Viguera AC, Baldessarini RJ, Friedberg J: Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998; 5: 293–306 CrossRef
e30.Hohagen F, Montero RF, Weiss E, et al.: Treatment of primary insomnia with trimipramine: an alternative to benzodiazepine hypnotics? Eur Arch Psychiatry Clin Neurosci 1994; 244: 65–72 CrossRef MEDLINE
e31.Baldwin DS, Montgomery SA, Nil R, Lader M: Discontinuation symptoms in depression and anxiety disorders. Int J Neuropsychopharmacol 2007; 10: 73–84 CrossRef MEDLINE
e32.Hindmarch I, Kimber S, Cockle SM: Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance. Int Clin Psychopharmacol 2000; 15: 305–18 CrossRef
e33.Judge R, Parry MG, Quail D, Jacobson JG: Discontinuation symptoms: comparison of brief interruption in fluoxetine and paroxetine treatment. Int Clin Psychopharmacol 2002; 17: 217–25 CrossRef
e34.Bogetto F, Bellino S, Revello RB, Patria L: Discontinuation syndrome in dysthymic patients treated with selective serotonin reuptake inhibitors: a clinical investigation. CNS Drugs 2002; 16: 273–83 CrossRef MEDLINE
e35.Boyer EW, Shannon M: The serotonin syndrome. N Engl J Med 2005; 352: 1112–20 CrossRef MEDLINE
e36.Benmansour S, Altamirano AV, Jones DJ, et al.: Regulation of the norepinephrine transporter by chronic administration of antidepressants. Biol Psychiatry 2004; 55: 313–6 CrossRef
e37.Kittler K, Lau T, Schloss P: Antagonists and substrates differentially regulate serotonin transporter cell surface expression in serotonergic neurons. Eur J Pharmacol 2010; 629: 63–7 CrossRef MEDLINE
e38.Mirza NR, Nielsen EØ, Troelsen KB: Serotonin transporter density and anxiolytic-like effects of antidepressants in mice. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 858–66 CrossRefMEDLINE
e39.Benmansour S, Owens WA, Cecchi M, Morilak DA, Frazer A: Serotonin clearance in vivo is altered to a greater extent by antidepressant-induced downregulation of the serotonin transporter than by acute blockade of this transporter. J Neurosci 2002; 22: 6766–72 CrossRef
e40.Klomp A, Hamelink R, Feenstra M, Denys D, Reneman L: Increased response to a 5-HT challenge after discontinuation of chronic serotonin uptake inhibition in the adult and adolescent rat brain. PLoS One 2014; 9: e99873 CrossRef MEDLINE PubMed Central
e41.Montgomery D: ECNP consensus meeting March 2000. Guidelines for investigating efficacy in GAD. Eur Neuropsychopharmacol 2002; 12: 81–7 CrossRef
e42.Coupland NJ, Bell CJ, Potokar JP: Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996; 16: 356–62 CrossRef
e43.Amsden GW, Georgian F: Orthostatic hypotension induced by sertraline withdrawal. Pharmacotherapy 1996; 16: 684–6.
e44.Phelps J: Tapering antidepressants: is 3 months slow enough? Med Hypotheses 2011; 77: 1006–8 CrossRef MEDLINE
e45.Keuthen NJ, Cyr P, Ricciardi JA, Minichiello WE, Buttolph ML, Jenike MA: Medication withdrawal symptoms in obsessive-compulsive disorder patients treated with paroxetine. J Clin Psychopharmacol 1994; 14: 206–7 CrossRef
e46.Benazzi F: Fluoxetine for clomipramine withdrawal symptoms. Am J Psychiatry 1999; 156: 661–2.
e47.Giakas WJ, Davis JM: Intractable withdrawal from venlafaxine treated with fluoxetine. Psychiatr Ann 1997; 27: 85–92 CrossRef
e48.Voderholzer U: Machen Antidepressiva abhängig?–Pro Psychiatr Prax 2018; 45: 344–5 CrossRef
e49.Lichtigfeld FJ, Gillman MA: The possible abuse of and dependence on major tranquillisers and tricyclic antidepressants. S Afr Med J 1994; 84: 5–6.
e50.WHO: International Statistical Classification of Diseases and Related health problems, 10th revision, 5th edition,: World Health Organization; 2015.
e51.Fava GA, Offidani E: The mechanisms of tolerance in antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 1593–602 CrossRef MEDLINE
e52.Bosman RC, Waumans RC, Jacobs GE, et al.: Failure to respond after reinstatement of antidepressant medication: a systematic review. Psychother Psychosom 2018; 87: 268–75 CrossRef MEDLINE PubMed Central
e53.Reidenberg MM: Drug discontinuation effects are part of the pharmacology of a drug. J Pharmacol Exp Ther 2011; 339: 324–8 CrossRef MEDLINE PubMed Central
e54.Reid JL, Campbell BC, Hamilton CA: Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists. Hypertension 1984; 6: II71–5 CrossRef
e55.O‘Brien ET, MacKinnon J: Propranolol and polythiazide in treatment of hypertension. Br Heart J 1972; 34: 1042–4 CrossRef MEDLINE PubMed Central
e56.Westermeyer J: Addiction to tranylcypromine (Parnate): a case report. Am J Drug Alcohol Abuse 1989; 15: 345–50 CrossRef
e57.Griffin N, Draper RJ, Webb MG: Addiction to tranylcypromine. Br Med J (Clin Res Ed) 1981; 283: 346 CrossRef MEDLINE PubMed Central
e58.Ainsworth K, Smith SE, Zetterström TS, Pei Q, Franklin M, Sharp T: Effect of antidepressant drugs on dopamine D1 and D2 receptor expression and dopamine release in the nucleus accumbens of the rat. Psychopharmacology (Berl)1998; 140: 470–7 CrossRef MEDLINE
e59.Heinz AJ, Beck A, Meyer-Lindenberg A, Sterzer P, Heinz A: Cognitive and neurobiological mechanisms of alcohol-related aggression. Nat Rev Neurosci 2011; 12: 400–13 CrossRef MEDLINE
e60.Hiemke C, Bergemann N, Clement HW, et al.: Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry 2018; 51: 9–62 CrossRef MEDLINE